相关实验视频

Updated: Jul 28, 2025

Murine Colitis Modeling using Dextran Sulfate Sodium DSS

Murine Colitis Modeling using Dextran Sulfate Sodium DSS

Published on: January 19, 2010

在热敏凝中的布德森-脂质体纳入复合物缓解了DSS诱导的小鼠性结肠炎

Dongliang Yang^1,2, Yuyu Zhao³, Liang Teng¹

¹Department of Pharmacy, The First Affiliated Hospital of Xinjiang Medical University, P. R. China.

Drug development and industrial pharmacy

|June 5, 2023

概括

一种新型的直肠配方,结合了布德索尼德脂质体 (Bud Lip) 和热敏凝 (Gel),可以有效地治疗小鼠的性结肠炎 (UC). 与其他治疗方法相比,这种Bud Lip-Gel配方显著降低了炎症和结肠损伤.

科学领域:

胃肠病学胃肠病学
药品制造药品制造药品制造
药物输送系统药物输送系统

背景情况:

性结肠炎 (UC) 是一种慢性炎症性肠病,需要有效的治疗策略.
通过直肠给药可为结肠疾病提供有针对性的治疗.
布德索尼德是一种用于管理UC的皮质类固醇,但其输送可以优化.

研究的目的:

开发和评估一种新型直肠配方的布德化物脂质体 (Bud Lip) 分散在热敏凝 (Gel) 中,用于治疗性结肠炎 (UC).
在UC的小鼠模型中,比较Bud Lip-Gel配方的抗炎活性和结肠粘膜保护与传统的布德索尼德透水,单独的布德索尼德脂质体和单独的布德索尼德凝的抗炎活性.

主要方法:

使用逆蒸发方法制备了布德化物脂质体 (Bud Lip).
布德利普通过冷方法分散在热敏凝 (PL407和PL188) 中.
德克斯硫酸 (DSS) 诱导的UC在雄性小鼠中被用各种配方 (Bud enema,Bud Lip,Bud Gel,Bud Lip-Gel,盐水) 进行了14天的直肠治疗.
评估了疾病活动指数 (DAI),宏观和微观结肠损伤得分,血清IL-6和IL-10水平,结肠组织TNF-α,IL-10和髓氧化酶 (MPO) 活性.

主要成果:

在UC小鼠模型中,Bud Lip-Gel配方显著缓解了炎症.
用Bud Lip-Gel治疗与较低的DAI,减少宏观和微观结肠损伤,以及对促炎性细胞因子 (TNF-α,IL-6) 和MPO活性的下调有关.
在治疗活跃UC时,Bud Lip-Gel与布德索尼德透水剂,布德索尼德脂质体和布德索尼德凝相比,表现出更高的疗效.

结论:

在热敏凝 (Bud Lip-Gel) 中的新型布德索尼德脂质体复合物有效地减轻了小鼠的UC症状.
这种配方表现出显著的抗炎作用,并保护结肠粘膜免受损伤.
布德唇凝代表了通过直肠给药治疗性结肠炎的有前途的潜在治疗策略.

关键词:

这就是Budesonide.药物输送系统是药物输送系统.脂质体是一种脂质体.热敏凝是一种热敏凝.性结肠炎是一种

更多相关视频

Investigating Intestinal Inflammation in DSS-induced Model of IBD

Investigating Intestinal Inflammation in DSS-induced Model of IBD

Published on: February 1, 2012

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

相关概念视频

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...